Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Cisplatin, Lenvatinib and Adebrelimab for Advanced ICC
NCT06298968Phase 2Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Apr 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab, lenvatinib in intrahepatic cholangiocarcinoma (ICC), sponsored by Nanfang Hospital, Southern Medical University. Started Apr 2024; status: recruiting.
02
Drugs
adebrelimablenvatinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06298968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06298968.